<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00355888</url>
  </required_header>
  <id_info>
    <org_study_id>M05-10070</org_study_id>
    <nct_id>NCT00355888</nct_id>
  </id_info>
  <brief_title>Safety Study of MBP-426 (Liposomal Oxaliplatin Suspension for Injection) to Treat Advanced or Metastatic Solid Tumors</brief_title>
  <official_title>A Phase I, Open Label Study of MBP-426 Given by Intravenous Infusion in Patients With Advanced or Metastatic Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mebiopharm Co., Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mebiopharm Co., Ltd</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether MBP-426 (liposomal oxaliplatin suspension&#xD;
      for injection) is safe and effective in the treatment of advanced or metastatic solid tumors.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Study Phase 1 Study Type (Interventional/Observational) Interventional Study Design Purpose:&#xD;
      Treatment Allocation: Nonrandomized trial Masking: Open Control: Dose Comparison Assignment:&#xD;
      Single Group Endpoint: Safety/Efficacy&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2006</start_date>
  <completion_date type="Actual">April 2009</completion_date>
  <primary_completion_date type="Actual">November 2008</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of dose-limiting toxicity, determination of maximum tolerated dose (MTD), and recommended Phase 2 dose</measure>
    <time_frame>Within 21 days of treatment administration</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Tumor shrinkage according to RECIST</measure>
    <time_frame>Measured every 6 weeks (i.e., every 2 cycles) while receiving study drug</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Limited exploratory assays</measure>
    <time_frame>Variable throughout study</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">39</enrollment>
  <condition>Cancer</condition>
  <arm_group>
    <arm_group_label>Open label study of MBP-426</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose escalation starting at 6 mg/m2, IV (in the vein) on Day 1 of each 21-day cycle. Number of Cycles: Up to 6 cycles, until unacceptable toxicity, disease progression, or intercurrent illness requires treatment discontinuation. Patients may continue treatment beyond 6 cycles if the Investigator determines that additional treatment would provide further benefit for the patient as long as toxicity remains acceptable.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MBP-426</intervention_name>
    <description>Dose escalation starting at 6 mg/m2, IV (in the vein) on Day 1 of each 21-day cycle. Number of Cycles: Up to 6 cycles, until unacceptable toxicity, disease progression, or intercurrent illness requires treatment discontinuation. Patients may continue treatment beyond 6 cycles if the Investigator determines that additional treatment would provide further benefit for the patient as long as toxicity remains acceptable.</description>
    <arm_group_label>Open label study of MBP-426</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Pathologically-confirmed malignancy that is locally advanced or metastatic solid tumor&#xD;
             and is refractory to standard therapy or for which conventional therapy is not&#xD;
             reliably effective or no effective therapy is available&#xD;
&#xD;
          -  18 years of age or older&#xD;
&#xD;
          -  ECOG Performance Status of 0, 1, or 2&#xD;
&#xD;
          -  Adequate clinical laboratory values:&#xD;
&#xD;
               -  absolute neutrophil count greater than or equal to 1500 cells/microliter&#xD;
&#xD;
               -  platelets greater than or equal to 100,000 cells/microliter&#xD;
&#xD;
               -  serum creatinine less than or equal to 1.5 x upper limit of normal (ULN) for the&#xD;
                  institution&#xD;
&#xD;
               -  creatinine clearance (calculated) &gt; 60 mL/min (using the Cockcroft-Gault&#xD;
                  equation)&#xD;
&#xD;
               -  bilirubin less than or equal to 1.5 x ULN&#xD;
&#xD;
               -  alanine transaminase (ALT) and aspartate transaminase (AST) less than or equal to&#xD;
                  2.5 x ULN (patients with known liver metastases may have up to 5 times ULN AST&#xD;
                  and ALT levels).&#xD;
&#xD;
          -  Ability to cooperate with treatment and follow-up schedules&#xD;
&#xD;
          -  Negative pregnancy test and using at least one form of contraception as approved by&#xD;
             the Investigator prior to study entry if a female patient of childbearing potential or&#xD;
             a male patient with a female partner of childbearing potential&#xD;
&#xD;
          -  Measurable disease as defined by RECIST criteria or non-measurable disease&#xD;
&#xD;
          -  Patients with known brain metastases may be included as long as they have been&#xD;
             clinically stable for one month or more, and are not receiving dexamethasone&#xD;
&#xD;
          -  Ability to maintain a central intravenous access (e.g. PICC, Groshong, or Hickman&#xD;
             line)&#xD;
&#xD;
          -  Signed informed consent prior to the start of any study specific procedures&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Received previous anticancer chemotherapy, immunotherapy, radiotherapy or any other&#xD;
             investigational therapy in the 4 weeks (6 weeks for nitrosoureas or mitomycin C) prior&#xD;
             to study entry&#xD;
&#xD;
          -  Received extensive prior radiotherapy to more than 30% of bone marrow reserves, or&#xD;
             prior bone marrow/stem cell transplantation&#xD;
&#xD;
          -  Any concomitant condition that could compromise the objectives of this study and the&#xD;
             patient's compliance&#xD;
&#xD;
          -  Pregnant or lactating women&#xD;
&#xD;
          -  Current malignancies of another type, with the exception of adequately treated in situ&#xD;
             cervical cancer and basal cell skin cancer or have demonstrated no evidence of disease&#xD;
             for 5 years or more&#xD;
&#xD;
          -  Clinically evident HIV, HBV, or HCV infection&#xD;
&#xD;
          -  Hematologic malignancy&#xD;
&#xD;
          -  Documented or known bleeding disorder&#xD;
&#xD;
          -  Requirements for therapeutic anticoagulation that increases INR or aPTT above the&#xD;
             normal range (low dose deep vein thrombosis [DVT] or line prophylaxis is allowed)&#xD;
&#xD;
          -  Congestive heart failure&#xD;
&#xD;
          -  Greater than Grade 1 peripheral neuropathy according to the National Cancer&#xD;
             Institute's Common Terminology Criteria for Adverse Events v3.0 (CTCAE version 3.0)&#xD;
&#xD;
          -  History of allergic reactions to platinum-based or liposomal agents&#xD;
&#xD;
          -  Creatinine clearance (calculated) less than or equal to 60 mL/min (using the&#xD;
             Cockcroft-Gault equation)&#xD;
&#xD;
          -  Receiving or initiating treatment with any other investigational agents&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alexandria Phan, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>M.D. Anderson Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>M.D. Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030-4009</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institute for Drug Development</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78245</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2009</verification_date>
  <study_first_submitted>July 24, 2006</study_first_submitted>
  <study_first_submitted_qc>July 24, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 25, 2006</study_first_posted>
  <last_update_submitted>November 27, 2014</last_update_submitted>
  <last_update_submitted_qc>November 27, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 2, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Cancer</keyword>
  <keyword>Advanced or Metastatic Solid Tumor</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

